argenx SE
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Karen Massey
- Full Time Employees
- 1,863
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Laarderhoogtweg 25 Amsterdam NH Netherlands 1101 EB
- IPO Date
- Jul 10, 2014
- Website
- argenx.com
- Similar Companies
- Business
- argenx SE argenx SE is a commercial-stage global immunology company that develops differentiated antibody-based therapies for severe autoimmune diseases; it offers VYVGART (efgartigimod), a first-in-class FcRn blocker approved in more than 30 countries including the US, EU, UK, Japan, Israel, China and Australia for generalized myasthenia gravis (gMG) in both intravenous and subcutaneous formulations (VYVGART SC), for chronic inflammatory demyelinating polyneuropathy (CIDP) in the US, China and Japan (as VYVDURA), and for immune thrombocytopenia (ITP) in Japan (as VYVDURA); it advances empasiprubart, a C2 complement inhibitor in Phase 3 for multiple autoimmune indications including multifocal motor neuropathy; and it progresses earlier-stage candidates such as ARGX-119 (MuSK agonist) in proof-of-concept for congenital myasthenic syndrome, amyotrophic lateral sclerosis and spinal muscular atrophy, alongside preclinical assets ARGX-213 (FcRn), ARGX-121 (IgA), ARGX-220 and ARGX-109 (IL-6). The company leverages its Immunology Innovation Program (IIP) and proprietary technologies including SIMPLE ANTIBODY platform, NHANCE, ABDEG, POTELLIGENT and DHS mutations to engineer antibodies; it operates through subsidiaries in the US (Boston), Belgium (Zwijnaarde), Japan (Tokyo), France, UK, Netherlands, Switzerland, Germany, Canada, Italy, Spain, Portugal, Australia and Austria; founded in 2008 and headquartered in Amsterdam, Netherlands, argenx SE conducts R&D primarily in Belgium and commercializes products globally targeting underserved patients in immunology. Recent developments include expansion of its ENHANZE license agreement with Halozyme in September 2024 by nominating four additional targets for a total of six including FcRn and C2 to enable subcutaneous formulations; a new manufacturing partnership expansion with FUJIFILM featuring a site in North Carolina; topline results from the registrational EMPASSION Phase 3 study in multifocal motor neuropathy for empasiprubart; plans for five registrational readouts in 2026 and submission of a supplemental BLA for seronegative gMG by end-2025; and combined 2025 R&D and SG&A guidance of approximately $2.5 billion.
Company News
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study
argenx: The Sjögren's Selloff Looks Overdone
argenx Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into argenx (ARGX)
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe
argenx shares drop after trial of Vyvgart in Sjögren's disease is halted
Argenx Halts Phase 3 Study in Rare Disease Following Futility Analysis
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble
Argenx Shares Plunge After Autoimmune-Disease Trial Halt
argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
Integrated Wealth Concepts LLC Sells 725 Shares of argenex SE $ARGX
BMY or ARGX: Which Is the Better Value Stock Right Now?
10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now?
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
Here's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 Months